e8vk
Table of Contents



SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K


Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 5, 2004

DYNAVAX TECHNOLOGIES CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

Commission File Number: 000-1029142

     
Delaware   33-0728374
(State or Other Jurisdiction of Incorporation)   (I.R.S. Employer Identification No.)

717 Potter Street, Suite 100
Berkeley, CA 94710-2722

(Address of Principal Executive Offices including zip code)

(510) 848-5100
(Registrant’s Telephone Number, Including Area Code)



 


TABLE OF CONTENTS

Item 7. Financial Statements and Exhibits.
Item 12. Results of Operations and Financial Condition.
SIGNATURES
EXHIBIT 99.1


Table of Contents

Item 7. Financial Statements and Exhibits.

c. Exhibits

     
Exhibit No.
  Description
99.1
  Press release of Dynavax Technologies Corporation, dated August 5, 2004.

Item 12. Results of Operations and Financial Condition.

On August 5, 2004, the Company issued a press release relating to the Company’s earnings for the second quarter of fiscal year 2004. A copy of the press release is attached as Exhibit 99.1.

The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 12 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

2


Table of Contents

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
  DYNAVAX TECHNOLOGIES CORPORATION
 
 
Date: August 5, 2004  By:   /s/ Dino Dina  
    Dino Dina, M.D.   
    President, Chief Executive Officer and Acting Chief Financial Officer   
 

3